📣 VC round data is live. Check it out!

Voyager Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Voyager Therapeutics and similar public comparables like Adimmune, Keros Therapeutics, Heron Therapeutics, Acepodia and more.

Voyager Therapeutics Overview

About Voyager Therapeutics

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.


Founded

2013

HQ

United States

Employees

172

Financials (LTM)

Revenue: $46M
EBITDA: ($122M)

EV

$74M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Voyager Therapeutics Financials

Voyager Therapeutics reported last 12-month revenue of $46M and negative EBITDA of ($122M).

In the same LTM period, Voyager Therapeutics generated $46M in gross profit, ($122M) in EBITDA losses, and had net loss of ($118M).

Revenue (LTM)


Voyager Therapeutics P&L

In the most recent fiscal year, Voyager Therapeutics reported revenue of $40M and EBITDA of ($128M).

Voyager Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of (317%) and net margin of (297%).

See analyst estimates for Voyager Therapeutics
LTMLast FY202320242025202620272028
Revenue$46M$40M$250M$80M$40M
Gross Profit$46M————
Gross Margin100%————
EBITDA($122M)($128M)$126M($79M)($128M)
EBITDA Margin(265%)(317%)51%(98%)(317%)
EBIT Margin(279%)(327%)49%(104%)(327%)
Net Profit($118M)($120M)$132M($65M)($120M)
Net Margin(256%)(297%)53%(81%)(297%)

Financial data powered by Morningstar, Inc.

Voyager Therapeutics Stock Performance

Voyager Therapeutics has current market cap of $234M, and enterprise value of $74M.

Market Cap Evolution


Voyager Therapeutics' stock price is $3.87.

Voyager Therapeutics share price increased by 3.9% in the last 30 days, and by 41.4% in the last year.

Voyager Therapeutics has an EPS (earnings per share) of $-1.98.

See more trading valuation data for Voyager Therapeutics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$74M$234M3.1%3.9%-5.5%41.4%$-1.98

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Voyager Therapeutics Valuation Multiples

Voyager Therapeutics trades at 1.6x EV/Revenue multiple, and (0.6x) EV/EBITDA.

See NTM and 2027E valuation multiples for Voyager Therapeutics

EV / Revenue (LTM)


Voyager Therapeutics Financial Valuation Multiples

As of May 5, 2026, Voyager Therapeutics has market cap of $234M and EV of $74M.

Voyager Therapeutics has a P/E ratio of (2.0x).

LTMLast FY202320242025202620272028
EV/Revenue1.6x1.8x0.3x0.9x1.8x
EV/EBITDA(0.6x)(0.6x)0.6x(0.9x)(0.6x)
EV/EBIT(0.6x)(0.6x)0.6x(0.9x)(0.6x)
EV/Gross Profit1.6x————
P/E(2.0x)(2.0x)1.8x(3.6x)(2.0x)
EV/FCF(0.6x)(0.5x)1.0x(3.9x)(0.5x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Voyager Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Voyager Therapeutics Margins & Growth Rates

In the most recent fiscal year, Voyager Therapeutics reported EBITDA margin of (317%) and net margin of (297%).

See estimated margins and future growth rates for Voyager Therapeutics

Voyager Therapeutics Margins

Last FY20242025202720282029
EBITDA Margin(317%)(98%)(317%)
EBIT Margin(327%)(104%)(327%)
Net Margin(297%)(81%)(297%)
FCF Margin(335%)(24%)(335%)

Voyager Therapeutics Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(68%)(50%)
EBITDA Growth(162%)63%
EBIT Growth(168%)58%
Net Profit Growth(149%)84%
FCF Growth(125%)617%

Data powered by FactSet, Inc. and Morningstar, Inc.

Voyager Therapeutics Operational KPIs

Voyager Therapeutics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $1.0M for the same period.

Access forward-looking KPIs for Voyager Therapeutics
LTMLast FY202320242025202620272028
Rule of 40(238%)————
Bessemer Rule of X(197%)————
Revenue per Employee—$0.2M———
Opex per Employee—$1.0M———
G&A Expenses to Revenue80%93%14%45%93%
R&D Expenses to Revenue298%334%37%159%334%
Opex to Revenue—427%51%204%427%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Voyager Therapeutics Competitors

Voyager Therapeutics competitors include Adimmune, Keros Therapeutics, Heron Therapeutics, Acepodia, Circio Holding, Binex, Egetis Therapeutics, Fennec Pharmaceuticals, Polaryx Therapeutics and Transgene.

Most Voyager Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Adimmune5.7x—(95.1x)—
Keros Therapeutics(0.2x)(0.2x)(0.6x)—
Heron Therapeutics2.1x2.0x(39.4x)22.1x
Acepodia21377.4x—(6.2x)—
Circio Holding——(46.9x)—
Binex2.5x2.4x33.8x81.9x
Egetis Therapeutics32.1x8.0x(7.4x)(30.4x)
Fennec Pharmaceuticals4.3x3.6x(25.5x)71.3x

This data is available for Pro users. Sign up to see all Voyager Therapeutics competitors and their valuation data.

Start Free Trial

Voyager Therapeutics Funding History

Before going public, Voyager Therapeutics raised $135M in total equity funding, across 3 rounds.


Voyager Therapeutics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Apr-15Series BBrookside Capital; Casdin Capital; Deerfield; Fidelity; Partner Fund Management; Wellington Management$60M——
Feb-15Strategic investmentGenzyme$30M—Voyager Therapeutics is a biotech company developing gene therapy treatments for central nervous system disorders, including advanced Parkinson's disease (VY-AADC01 in Phase 1b), ALS, Friedreich’s ataxia, Huntington’s disease, and spinal muscular atrophy. In February 2015, Aventis (Sanofi/Genzyme affiliate) invested $30 million in Voyager as part of a strategic collaboration, following a $45 million Series A from Third Rock Ventures in January 2014 and a $49 million round from Fidelity, Brookside, and Partners Investments in April (total private funding $124 million pre-IPO). The Genzyme deal included $100 million upfront from Sanofi Genzyme for options to license programs in Huntington’s (VY-HTT01) and Friedreich’s ataxia (VYFXN01), with up to $745 million in milestones, while Voyager retained certain U.S. rights. ownership stakes post-investment show Third Rock at 52.6%, Aventis at 11.2%, Fidelity at 7.5%, Brookside at 5.6%, and Partners at 5.2%. Later in 2015, Voyager filed for an $86.3 million IPO to fund clinical development of VY-AADC01 and preclinical programs. Sanofi later terminated parts of the collaboration, returning ex-U.S. rights to Voyager for Huntington’s and Friedreich’s programs (with $10 million payment to Voyager), and Voyager transferred Friedreich’s rights to Neurocrine Biosciences for $165 million upfront plus up to $1.7 billion in milestones.
Feb-14Series AThird Rock Ventures$45M—Voyager Therapeutics was launched by Third Rock Ventures as part of its third fund, with the firm typically providing large Series A rounds of $40-50 million as the sole initial investor to retain significant ownership. Voyager Therapeutics and Editas Medicine, both from this fund, went public in 2015 and 2016 respectively. Third Rock's strategy focuses on technology platform companies developing multiple drugs for growth opportunities.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Voyager Therapeutics

When was Voyager Therapeutics founded?Voyager Therapeutics was founded in 2013.
Where is Voyager Therapeutics headquartered?Voyager Therapeutics is headquartered in United States.
How many employees does Voyager Therapeutics have?As of today, Voyager Therapeutics has over 172 employees.
Who is the CEO of Voyager Therapeutics?Voyager Therapeutics' CEO is Alfred W. Sandrock.
Is Voyager Therapeutics publicly listed?Yes, Voyager Therapeutics is a public company listed on Nasdaq.
What is the stock symbol of Voyager Therapeutics?Voyager Therapeutics trades under VYGR ticker.
When did Voyager Therapeutics go public?Voyager Therapeutics went public in 2015.
Who are competitors of Voyager Therapeutics?Voyager Therapeutics main competitors include Adimmune, Keros Therapeutics, Heron Therapeutics, Acepodia, Circio Holding, Binex, Egetis Therapeutics, Fennec Pharmaceuticals, Polaryx Therapeutics, Transgene.
What is the current market cap of Voyager Therapeutics?Voyager Therapeutics' current market cap is $234M.
What is the current revenue of Voyager Therapeutics?Voyager Therapeutics' last 12 months revenue is $46M.
What is the current revenue growth of Voyager Therapeutics?Voyager Therapeutics revenue growth (NTM/LTM) is 27%.
What is the current EV/Revenue multiple of Voyager Therapeutics?Current revenue multiple of Voyager Therapeutics is 1.6x.
Is Voyager Therapeutics profitable?No, Voyager Therapeutics is not profitable.
What is the current EBITDA of Voyager Therapeutics?Voyager Therapeutics has negative EBITDA and is not profitable.
What is Voyager Therapeutics' EBITDA margin?Voyager Therapeutics' last 12 months EBITDA margin is (265%).
What is the current EV/EBITDA multiple of Voyager Therapeutics?Current EBITDA multiple of Voyager Therapeutics is (0.6x).
What is the current FCF of Voyager Therapeutics?Voyager Therapeutics' last 12 months FCF is ($119M).
What is Voyager Therapeutics' FCF margin?Voyager Therapeutics' last 12 months FCF margin is (259%).
What is the current EV/FCF multiple of Voyager Therapeutics?Current FCF multiple of Voyager Therapeutics is (0.6x).
How many companies Voyager Therapeutics has acquired to date?Voyager Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Voyager Therapeutics has invested to date?Voyager Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Voyager Therapeutics

Lists including Voyager Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial